What question did this study set out to answer?

To examine the treatment patterns in metastatic castration-resistant prostate cancer (mCRPC) following progression from metastatic hormone-sensitive prostate cancer (mHSPC).

April 25, 2026

Real-world treatment patterns in metastatic castration-resistant prostate cancer progressing from metastatic hormone-sensitive prostate cancer

Key Points

To examine the treatment patterns in metastatic castration-resistant prostate cancer (mCRPC) following progression from metastatic hormone-sensitive prostate cancer (mHSPC).
Analysis of treatment patterns for mCRPC after mHSPC management changes.
Focus on first-line therapies, particularly androgen receptor pathway inhibitors (ARPIs).
ARPIs were commonly used as the first-line therapy in mCRPC.
Despite the availability of other treatments, their use remained limited even with clinical support.

Abstract

Despite changes in mHSPC management, ARPIs remain a frequent choice of first-line mCRPC therapy, with back-to-back ARPI use common. Even with the availability of other therapies beyond ARPIs, and the clinical evidence supporting use of agents beyond ARPIs, treatment with these therapies was limited.

Real-world treatment patterns in metastatic castration-resistant prostate cancer progressing from metastatic hormone-sensitive prostate cancer

Key Points

Abstract

Cite This Study